bull case. directionally supported by early trajectory
18 million steady-state patients, $2,500 in annual net revenue per patient, and a 60% gross margin, or similar combinations. Under these scenarios, oral Wegovy would generate $20-30 billion in annual gross profit. ๐ค $NVO